A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing

European Journal of Immunology

Volumn 33, Issue 5, 2003, Pages 1334-1340

  Grosse Hovest, Ludger ^a   Hartlapp, Ingo ^a   Marwan, Wolfgang ^b   Brem, Gottfried ^c   Rammensee, Hans Georg ^a   Jung, Gundram ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^c UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

Bispecific antibody; CD28; Immunotherapy; Recombinant antibody; T cell activation

Indexed keywords

BISPECIFIC ANTIBODY; CD28 ANTIGEN; CD3 ANTIGEN; DIMER; PROTEOGLYCAN; RECOMBINANT ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; TUMOR VACCINE;

ANTIBODY PRODUCTION; ANTIGEN ANTIBODY REACTION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL KILLING; CONTROLLED STUDY; CYTOLYSIS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VIVO STUDY; MONONUCLEAR CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PURIFICATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TUMOR CELL;

ANTIBODIES, BISPECIFIC; ANTIGENS, CD28; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; LYMPHOCYTE ACTIVATION; MELANOMA; PROTEOGLYCANS; RECOMBINANT PROTEINS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0038297196     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200323322     Document Type: Article

References (31)

1. Lenschow, D. J., Walunas, T. L. and Bluestone, J. A., CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 1996. 14: 233-258.
2. Hurwitz, A. A., Kwon, D. K. and van Elsas, A., Costimulatory wars: the tumor menace. Curr. Opin. Immunol. 2000. 12: 589-596.
3. Hellström, K. E., Hellström, I. and Chen, L., Can costimulated tumor immunity be therapeutically efficious? Immunol. Rev. 1995. 145: 123-145.
4. Levitsky, H. I., Montgomery, J., Ahmadzadeh, M., Staveley-OCaroll, K., Guarneri, F., Longo, D. L. and Kwak, L. W., Immunization with granulocate-macrophage colony stimulatin factor-transduced, but not B7-1 transduced lymphoma cells primes idiotype specific T cells and generates potent systemic antitumor immunity. J. Immunol. 1996. 156: 3858-3856.
5. Cayeux, S., Beck C., Aicher, A., Dorken, B. and Blankenstein, T., Tumor cells cotransfected with interleukin-7 and B7-1 genes induce CD25 and CD28 on tumor infiltrating lymphocytes and are strong vaccines. Eur. J. Immunol. 1995. 25: 2325-2331.
6. Zitvogel, L., Robbins, P. D., Storkus, W. J., Clarke, M. R., Maeurer, M. J., Campbell, R. L., Davis, C. G., Tahara, H., Schreiber, R. D. and Lotze, M. T., Interleukin-12 and B7. 1 costimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur. J. Immunol. 1996. 26: 1335-1341.
7. Sturmhoefel, K., Lee, K., Gray G. S., Thomas, J., Zollner, R., O'Toole, M., Swiniarski, H., Dorner, A. and Wolf, S., Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as a vaccine adjuvant. Cancer Res. 1999. 59: 4964-4972.
8. Notter, M., Willinger, T. Erben, U. and Thiel, E., Targeting of a B7 (CD80) immunoglobulin G fusion protein to acute myeloid leukemia blasts increases their costimulatory activity for autologeous remission T cells. Blood 2001. 97: 3138-3145.
9. Gerstmayer, B., Altenschmidt, U., Hoffmann, M. and Wels, W., Costimulation and T cell proliferation by a chimeric B7-2 antibody fusion protein specifically targeted to cells expressing the erbB2 proto-oncogene. J. Immunol. 1997. 158: 4584-4590.
10. Moro, M., Gasparri, A. M., Pagano, S., Bellone, M., Tornaghi, P., Veglia, F. Corti, A., Casorati, G. and Dellabona, P., Induction of therapeutic T cell immunity by tumor targeting with soluble recombinant B7 immunoglobulin costimulatory molecules. Cancer Res. 1999. 59: 2650-2656.
11. Krummel, M. F. and Allison, J. P., CD28 and CTLA4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 1995. 182: 459-465.
12. Jung, G. and Müller-Eberhard, H. J., An in vitro model for tumor immunotherapy with antibody heteroconjugates. Immunol. Today 1988. 9: 257-260.
13. Große-Hovest, L., Brandl, M., Dohlsten, M., Kalland, T., Wilmanns, W. and Jung, G., Tumor growth inhibition with bispecific antibody fragments in a syngeneic mouse melanoma model: The role of targeted T cell costimulation via CD28. Int. J. Cancer 1999. 80: 138-144.
14. Jung, G. Freimann, U., von Marschall, Z., Reisfeld, R. A. and Wilmanns, W., Target cell induced T cell activation with bi- and trispecific antibody fragments. Eur. J. Immunol. 1991. 21: 2431-2435.
15. Bohlen, H., Manzke, O., Patel, B. et al., Cytolysis of leukemic B cells by T cells activated via two bispecific antibodies. Cancer Res. 1993. 53: 4310-4314.
16. Renner, C., Jung, W., Sahin, U. et al., Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science 1994. 264: 833-835.
17. Akerstrom, B. and Bjoerk. L., Protein L: an immunoglobulin light chain binding protein. J. Biol. Chem. 1989. 264: 19740-19746.
18. Alfthan, K., Takkinen, K., Sizmann, D., Söderlund, H. and Teeri, T. T., Properties of a single chain antibody containing different linker peptides. Protein Eng. 1995. 8: 725-731.
19. Holliger, P., Prospero, T. and Winter, G., "Diabodies": small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA 1993. 90: 6444-6448.
20. Kipriyanov, S. M., Moldenhauer, G., Schuhmacher, J., Cochlovius, B., von der Lieth, C. W., Matys, R. and Little, M., Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J. Mol. Biol. 1999. 293: 41-56.
21. Loffler, A., Kufer, P., Lutterbuse, R. et al., A recombinant bispecific single chain antibody, CD19 × CD3, induces rapid and high lymphoma directed cytotoxicity by unstimulated T lymphocytes. Blood 2000. 95: 2098-2103.
22. Bischof, A., Hara, T., Lin, C. H., Beyers, A. D. and Hunig, T., Autonomous induction of proliferation, JNK and NFkappaB activation in primary resting T cells by mobilized CD28. Eur. J. Immunol. 2000. 30: 876-882.
23. Siefken, R., Klein-Heßling, S., Serfling, E. Kurrle, R. and Schwinzer, R. A., CD28 associated signaling pathway leading to cytokine gene transcription and T cell proliferation without TCR engagement. J. Immunol. 1998. 161: 1645-1651.
24. 2 in ovarian carcinoma patients. Int. J. Cancer 1996. 66: 477-483.
25. Kroesen, B. J., Buter, J., Sleijfer. D. T., Jansen, R. A. J., van der Graaf, W. T. A., The, T. H., deLeij, L. and Mulder, N. H., Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2. Br. J. Cancer 1994. 70: 652-661.
26. Molema, G., Cohen Tervaert, J. W., Kroesen, B. J., Helfrich, W., Meijer, D. K. and deLeij, L. F., CD3 directed bispecific antibodies induce increased lymphocyte endothelial cell interactions in vitro. Br. J. Cancer 2000. 82: 472-479.
27. Jung, G., Martin, D. E. and Müller-Eberhard, H. J., Induction of cytotoxicity in human peripheral blood mononuclear cells by monoclonal antibody OKT3. J. Immunol. 1987. 139: 639-644.
28. Guo, Y. J., Che, X. Y., Shen, F. et al., Effective tumor vaccines generated by in vitro modification of tumor cells with cytokines and bispecific monoclonal antibodies. Nat. Med. 1997. 3: 451-455.
29. Delnes, C., Cochlovius, B., Schmidt, S., Kipriyanov, S., Rode, H. J. and Little, M., Apoptosis of a human melanoma cell line specifically induced by membrane bound single chain antibodies. J. Immunol. 1999. 163: 3948-3956.
30. Little, M., Kipriyanov, S. M., Le Gall, F. and Moldenhauer, G., Of mice and men: hybridoma and recombinant antibodies. Immunol. Today 2000. 21: 364-370.
31. Weidle, U. H., Lenz, H. and Brem, G., Genes encoding a mouse monoclonal antibody are expressed in transgenic mice, rabbits and pigs. Gene 1991. 98: 185-191.